Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | IDUA | P35475 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9795940 | 1.00 | LMNA (0.36) | LMNAAPPIDUAGBA1GAA | |
| SCHEMBL2461308 | 1.00 | LMNA (0.36) | LMNAAPPIDUAGBA1GAA | |
| SCHEMBL2461938 | 1.00 | LMNA (0.36) | LMNAAPPIDUAGBA1GAA | |
| SCHEMBL12311529 | 1.00 | LMNA (0.36) | LMNAAPPIDUAGBA1GAA | |
| SCHEMBL2468220 | 1.00 | LMNA (0.36) | LMNAAPPIDUAGBA1GAA | |
| SCHEMBL2517248 | 1.00 | LMNA (0.36) | LMNAAPPIDUAGBA1GAA | |
| SCHEMBL9796346 | 1.00 | LMNA (0.36) | LMNAAPPIDUAGBA1GAA | |
| SCHEMBL2517246 | 1.00 | LMNA (0.36) | LMNAAPPIDUAGBA1GAA | |
| SCHEMBL9796369 | 0.76 | — | — | |
| SCHEMBL27913293 | 0.72 | LMNA (0.46) | LMNAAPPGBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE | 2009-08-27 | — | — | US | claimed |
| US-20080138379-A1 | Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy | JENNINGS-SPRING BARBARA L | 2008-06-12 | — | — | US | claimed |
| US-20160143927-A1 | Compounds, Methods, and Treatments for Abnormal Signaling Pathways for Prenatal and Postnatal Development | JENNINGS BARBARA BROOKE (US) | 2016-05-26 | — | — | US | disclosed |
| US-20110218176-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS-SPRING BARBARA BROOKE | 2011-09-08 | — | — | US | disclosed |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160143927-A1 | Compounds, Methods, and Treatments for Abnormal Signaling Pathways for Prenatal and Postnatal Development | PDK1, PKM, PDK2 | LMNA 863/4885APP 3759/4885IDUA 3532/4885 |
| US-20110218176-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | PDK1, PKM, PDK2 | LMNA 863/4885APP 3759/4885IDUA 3532/4885 |
| US-20080138379-A1 | Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy | PGF, ERH, BRCA1 | LMNA 372/4885APP 4300/4885IDUA 2080/4885 |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | SHH, ERH, CDK5 | LMNA 1460/4885APP 4014/4885IDUA 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.